Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead  J. Carlijn Van Gaal, Eveline S.J.M. De Bont, Suzanne E.J. Kaal, Yvonne Versleijen-Jonkers, Winette T.A. van der Graaf  Critical Reviews in Oncology / Hematology  Volume 82, Issue 3, Pages 259-279 (June 2012) DOI: 10.1016/j.critrevonc.2011.06.005 Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 a. Incidence rates of all subtypes of RMS in patients 0–29 years of age [35,37]. *Data regarding patients with RMS >14 years in Europe were not available. b. Incidence of ERMS and ARMS in the childhood population. Copied from Ognjanovic et al. [33]. Copyright 2011 American Cancer Society. This material is reproduced with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Critical Reviews in Oncology / Hematology 2012 82, 259-279DOI: (10.1016/j.critrevonc.2011.06.005) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 Clinical trial availability explicitly for sarcoma/RMS by phase (I/II/III), type of intervention (chemotherapy, targeted therapy, immune-related therapy, stem cell transplantation (SCT), radiotherapy, and others) and for each year of age 0–55 years over the 10-year period 1st January 2001–1st January 2011. It is of note that our search on sarcoma/rhabdomyosarcoma results in a major underestimation of phase I trials available in these patients of adult age, because this indication is often not mentioned explicitly in study description. Critical Reviews in Oncology / Hematology 2012 82, 259-279DOI: (10.1016/j.critrevonc.2011.06.005) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions